How Clay Siegall Has Helped in Shaping Seattle Genetics

Dr Siegall serves as the President, CEO and the Chairman of the board of Seattle Genetics, Inc. He acquired his B.S in Zoology from Maryland University and a Genetics PhD from George Washington University. He also cofounded Seattle Genetics back then in 1998 after working for Bristol Myers Squibb Pharmaceutical Research Institute for 6 years. Dr. Siegall also built the company with a strong emphasis on cancer therapies. The company is established on a foundation of rigorous research, drug development processes and scientific innovation.

Dr. Siegall’s Achievements

Seattle Genetics has gained critical acclaim due to its antibody drug conjugate (ADC) platform. The platform targets diverse autoimmune and cancer indications. Under Dr. Siegall’s management, the company has acquired several strategic licenses mainly for its ADC technology. These include AbbVie, GlaxoSmithKline, Pfizer and Genentech (Roche). These licenses have accumulated over 300 million dollars to date. As a sign of progress, there are over 20 ADCs in the clinical sector using the company’s technology. Dr. Siegall’s capital raising ideas have enabled Seattle Genetics to secure more than 675 million dollars through private and public funding.

Dr. Siegall was a keynote speaker at the CHI’s 5th Annual Antibody Drug Conjugates Conference held in Boston. In his speech, he talked about how ADCETRIS (brentuximab vedotin) is being used to treat over 15,000 lymphoma patients globally. He also mentioned that Seattle Genetics has collaborated with several leading pharmaceutical and biotechnology companies.

His Perspectives Regarding ADC Technology

Dr. Siegall highlighted that his company is leveraging the experience gathered from ADC and driving innovation into ADC technology. He also mentioned that two pipeline programs have launched in addition to the ADCETRIS product. These include SGN-CD19A and SGN-CD33A. SGN-CD33A was developed to provide treatment to acute leukemia cells. On the other hand SGN-CD19A is an antibody drug conjugate that targets CD19 that is a protein found in B-cell malignancies.

Information on the technologies that are used in both pipeline programs was presented to the American Association for Cancer Research (AACR) Annual meeting in April 2015. This information focused on the new linker, antibody, cytotoxic payload components and drug designs for the pipeline programs.

Learn more:

http://www.xconomy.com/author/csiegall/

https://www.crunchbase.com/person/clay-b-siegall#/entity

Leave a Reply

Recent Posts

Archives

Categories

Meta

Read On: